Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum

Japanese Journal of Clinical Oncology

Volumn 35, Issue 5, 2005, Pages 251-255

  Chang, Heung Moon ^a   Kim, Tae Won ^a   Ryu, Baek Yeol ^b   Choi, Seong Jun ^b   Park, Yeon Hee ^b   Lee, Jung Shin ^a   Kim, Woo Kun ^a   Kang, Yoon Koo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

Author keywords

Carboplatin; Gastric cancer; Paclitaxel

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; EPTAPLATIN; FLUOROURACIL; PACLITAXEL; PLATINUM DERIVATIVE; RANITIDINE; ANTINEOPLASTIC AGENT; PLATINUM;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MALE; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; ADENOCARCINOMA; BIOASSAY; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; MIDDLE AGED; NEUROLOGIC DISEASE; STOMACH TUMOR;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; NEUTROPENIA; PACLITAXEL; PLATINUM; STOMACH NEOPLASMS;

EID: 21744450426     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi077     Document Type: Article

References (26)

1. Hoel DG, Davis DL, Miller AB, Sondik EJ, Swerdlow AJ. Trends in cancer mortality in 15 industrialized countries, 1969-1986. J Natl Cancer Inst 1992;84:313-20.
2. Shin HR, Ahn YO, Bae JM, Shin MH, Lee DH, Lee CW, et al. Cancer incidence in Korea. Cancer Res Treat 2002;34:405-8.
3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
4. Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994;5:189-90.
5. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
6. Kim DK, Kim G, Gam J, Cho YB, Kim HT, Tai JH, et al. Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) complexes. J Med Chem 1994;37:1471-85.
7. Kim NK, Im SA, Kim DW, Lee MH, Jung CW, Cho EK, et al. Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. Cancer 1999;86:1109-15.
8. Kim NK, Bang Y, Heo DS, Kang Y, Kang WK, Kim H, et al. SKI2053R and 5-fluorouracil (5-FU) in advanced gastric adenocarcinoma: Phase II clinical trial. Proc Am Soc Clin Oncol 2000;19;323a (abstract).
9. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-14.
10. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II study of taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998;4:269-74.
11. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999;85:295-301.
12. Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LO, Scalabrini-Neto AO. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: A novel, safe, and effective regimen. Am J Clin Oncol 1999;22:580-6.
13. Philip PA, Zalupski MM, Gadgeel S, Hussain M, Shields A. A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. Semin Oncol 1997;24:S86-8.
14. Gadgeel SM, Shields AF, Heilbrun LK, Labadidi S, Zalupski M, Chaplen R, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol 2003;26:37-41.
15. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961;13:346-53.
16. Vanhoefer U, Wilke H, Weh HJ, Clemens M, Harstrick A, Stahl M, et al. Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol 1994;5:850-1.
17. Di Bartolomeo M, Bajetta E, Somma L, Carnaghi C, Bandieri E, Del Vecchio M, et al. Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. Oncology 1996;53:54-7.
18. Hartmann JT, Kanz L, Bokemeyer C. Phase II study of continuous 120-hour-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma. Anticancer Res 2000;20:1177-82.
19. Chang YF, Li LL, Wu CW, Liu TY, Lui WY, P'eng FK, et al. Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 1996;77:14-8.
20. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, et al. An early phase Ii study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998;21:416-9.
21. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 1998;9:307-10.
22. Stathopoulos GP, Rigatos SK, Fountzilas G, Polyzos A, Stathopoulos JG. Paclitaxel and carboplatin in pretreated advanced gastric cancer: A phase II study. Oncol Rep 2002;9:89-92.
23. Takahashi H, Sasaki Y, Saijo N, Sakurai M, Nakano H, Nakagawa K, et al. In vitro colony inhibition of carboplatin against stomach and lung cancer cell lines in comparison with cisplatin. Cancer Chemother Pharmacol 1987;19:197-200.
24. Beer M, Cavalli F, Kaye SB, Lev LM, Clavel M, Smyth J, et al. A phase II study of carboplatin in advanced or metastatic stomach cancer. Eur J Cancer Clin Oncol 1987;23:1565-7.
25. Preusser P, Wilke H, Achterrath W, Lenaz L, Stahl M, Casper J, et al. Phase II study of carboplatin in untreated inoperable advanced stomach cancer. Eur J Cancer 1990;26:1108-9.
26. Jekunen AP, Christen RD, Shalinsky DR, Howell SB. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994;69:299-306.